The scope is to understand:
The utility of β-amyloid imaging in the context of other biomarkers and diagnostic tests in current clinical practise in AD.
The use of β-amyloid imaging in the enrichment of preclinical/pre-dementia clinical trial populations and its incorporation in disease modelling and in adaptive clinical trials.
In-vivo β-amyloid imaging provides information on distribution and severity of one of the two key histo-pathological hallmarks of Alzheimer’s Disease (AD). However its role and value in patient diagnostics/current care pathways as well as its use in patient enrichment in therapeutic trials for pre-clinical/early AD has to be defined yet.
Collecting data and coming to some relevant conclusions on how β-amyloid imaging can aid diagnosis, management and success in preclinical/pre-dementia clinical trials for AD, will facilitate the development of new treatments. It will also improve management, and ultimately quality of life, in patients treated with the drugs available today.